FREMONT, Calif., Oct. 8, 2015 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on gastrointestinal and cardio-renal diseases, today announced that
clinical data for the Company's lead product candidate, tenapanor,
will be presented at the 2015 American College of Gastroenterology
(ACG) Annual Meeting. The presented findings will include
measures of sustained response in IBS-C patients enrolled in the
Company's 12-week, double blind, placebo-controlled, randomized
Phase 2 trial. The meeting will be held in Honolulu, HI, from October 16 through October 21, 2015. The abstract
is currently available on the ACG website at
http://acgmeetings.gi.org/.
ACG 2015 Poster Presentation:
Title: Tenapanor's
Sustained Response in Patients With Constipation Predominant
Irritable Bowel Syndrome: Post-hoc Analysis From a 12-Week,
Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial, by
William D. Chey, Anthony J. Lembo, M.D., David P. Rosenbaum, Ph.D.
Program Number: 1014
Date & Location: Monday, October 19, 2015, 10:00 a.m.-3:30 p.m. Local Time; Exhibit Hall,
Hawaii Convention Center
About Irritable Bowel Syndrome with Constipation
(IBS-C)
IBS-C is a gastrointestinal disorder in which abdominal pain or
discomfort is associated with constipation, significantly affecting
health and quality of life. It is unknown what causes IBS-C. There
is no specific test or biomarker for IBS-C, and therefore, its
presence is diagnosed by symptoms and by eliminating other
disorders. IBS-C is very similar to chronic constipation, but is
clinically distinguished by its significant pain component.
Based on reports in the literature regarding the prevalence of
IBS in the U.S. population and the percentage of individuals who
have IBS-C as opposed to other forms of
IBS, Ardelyx estimates that approximately 1.4 percent of
the U.S. population has IBS-C, or about 4.4 million individuals. Of
those, approximately 1.0 million patients have been diagnosed with
IBS-C. Additionally, it is estimated that there are about 6.6
million IBS-C patients in Europe and about 3.4 million
patients in Japan.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal tract to treat gastrointestinal
and cardio-renal diseases. Ardelyx has developed a proprietary drug
discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor, which it is evaluating for the treatment of
IBS-C and for the control of hyperphosphatemia in CKD patients on
dialysis. In addition to tenapanor, Ardelyx is developing RDX022, a
non-absorbed polymer for the treatment of hyperkalemia, or high
potassium, in kidney and heart disease patients. Ardelyx is also
advancing several research programs focused in gastrointestinal and
cardio-renal diseases. Ardelyx is located in Fremont, California. For more information,
please visit Ardelyx's website at www.ardelyx.com.
Forward Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Ardelyx,
they are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor of
the Private Securities Reform Act of 1995, including the potential
for tenapanor in treating IBS-C and hyperphosphatemia in CKD
patients on dialysis, and the potential for RDX022 in treating
hyperkalemia in kidney and heart disease patients. Such
forward-looking statements involve substantial risks and
uncertainties that could cause the development of tenapanor, or
Ardelyx's future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in research and the
clinical development process. Ardelyx undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating
to Ardelyx's business in general, please refer
to Ardelyx's quarterly report on Form 10-Q filed with
the Securities and Exchange Commission on August 12,
2015, and its future current and periodic reports to be filed with
the Securities and Exchange Commission.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-phase-2-data-for-tenapanor-in-ibs-c-patients-at-the-2015-american-college-of-gastroenterology-annual-meeting-300156955.html
SOURCE Ardelyx